NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's top executives, including CEO Chris Smith, CFO Jeff Sherman, and CCO Warren Stone, will engage in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.
The presentation will be webcast live and can be accessed online through a provided link. For those unable to attend or watch live, a replay will be made available on the Investor Relations section of NeoGenomics' website at ir.neogenomics.com.
NeoGenomics, Inc. (NASDAQ: NEO), un'azienda leader nei servizi di test oncologici, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. I dirigenti principali dell'azienda, tra cui l'Amministratore Delegato Chris Smith, il Direttore Finanziario Jeff Sherman e il Direttore Commerciale Warren Stone, parteciperanno a una discussione informale di persona venerdì 6 settembre 2024, alle 10:45 ET a New York City.
La presentazione sarà trasmessa in diretta e sarà accessibile online tramite un link fornito. Per coloro che non possono partecipare o guardare in diretta, sarà disponibile una registrazione nella sezione Relazioni con gli Investitori del sito web di NeoGenomics su ir.neogenomics.com.
NeoGenomics, Inc. (NASDAQ: NEO), una empresa líder en servicios de pruebas oncológicas, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. Los principales ejecutivos de la empresa, incluido el CEO Chris Smith, el CFO Jeff Sherman y el CCO Warren Stone, participarán en una charla informal en persona el viernes 6 de septiembre de 2024, a las 10:45 a.m. ET en la ciudad de Nueva York.
La presentación se transmitirá en vivo y estará disponible en línea a través de un enlace proporcionado. Para aquellos que no puedan asistir o ver en vivo, se hará disponible una repetición en la sección de Relaciones con Inversores en el sitio web de NeoGenomics en ir.neogenomics.com.
NeoGenomics, Inc. (NASDAQ: NEO), 선도적인 종양학 검사 서비스 회사가 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참석한다고 발표했습니다. CEO 크리스 스미스, CFO 제프 셔먼, CCO 워렌 스톤을 포함한 회사의 주요 경영진이 2024년 9월 6일 금요일 오전 10시 45분 ET 뉴욕에서 대면 화상 대화를 진행할 예정입니다.
프레젠테이션은 실시간 웹 캐스트로 방송되며 제공된 링크를 통해 온라인에서 접근할 수 있습니다. 참석하지 못하거나 실시간으로 시청할 수 없는 분들을 위해, 네오젠오믹스 웹사이트의 투자자 관계 섹션에 재생이 제공될 예정입니다 ir.neogenomics.com.
NeoGenomics, Inc. (NASDAQ: NEO), une entreprise leader dans les services de tests oncologiques, a annoncé sa participation à la 22ème conférence annuelle mondiale sur la santé de Morgan Stanley. Les principaux dirigeants de l'entreprise, y compris le PDG Chris Smith, le CFO Jeff Sherman et le CCO Warren Stone, participeront à une discussion informelle en personne le vendredi 6 septembre 2024, à 10h45 ET à New York.
La présentation sera diffusée en direct et accessible en ligne via un lien fourni. Pour ceux qui ne peuvent pas assister ou regarder en direct, une rediffusion sera disponible dans la section Relations Investisseurs du site Internet de NeoGenomics sur ir.neogenomics.com.
NeoGenomics, Inc. (NASDAQ: NEO), ein führendes Unternehmen im Bereich der Onkologie-Testdienste, hat seine Teilnahme an der 22. Jahrestagung für globale Gesundheitsversorgung von Morgan Stanley bekannt gegeben. Die Führungskräfte des Unternehmens, einschließlich CEO Chris Smith, CFO Jeff Sherman und CCO Warren Stone, werden an einem persönlichen Gespräch am Kamin am Freitag, den 6. September 2024, um 10:45 Uhr ET in New York City teilnehmen.
Die Präsentation wird live über das Internet übertragen und über einen bereitgestellten Link online zugänglich sein. Für diejenigen, die nicht teilnehmen oder live zuschauen können, wird eine Wiederholung im Bereich Investor Relations auf der Website von NeoGenomics unter ir.neogenomics.com bereitgestellt.
- None.
- None.
The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.
Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829956644/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
When is NeoGenomics (NEO) participating in the Morgan Stanley Healthcare Conference?
What time is NeoGenomics' (NEO) presentation at the Morgan Stanley conference?
Who will represent NeoGenomics (NEO) at the Morgan Stanley Healthcare Conference?
How can I watch NeoGenomics' (NEO) presentation at the Morgan Stanley conference?
Where is the Morgan Stanley Healthcare Conference that NeoGenomics (NEO) is attending taking place?
